RIGL Stock Analysis: Buy, Sell, or Hold?
RIGL - Rigel Pharmaceuticals Inc. (New)
$34.86
-0.30 (-0.85%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 03, 2026
29d
Get Alerted When RIGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called RIGL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RIGL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: RIGL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.78
Based on -20.2% avg growth
INTRINSIC VALUE TODAY
$6.69
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RIGL is currently trading at $34.86, which is considered oversold relative to its 30-day fair value range of $36.49 to $43.21. The stock's valuation (Forward PE: 9.4) is in line with its historical norms (10.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.5% over the next few years. This pessimistic expectation contrasts with the company's recent 108.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RIGL is in a uptrend. The price is currently testing key support at $33.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RIGL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+48.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RIGL is in a uptrend. The price is currently testing key support at $33.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RIGL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+48.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$36.49 -
$43.21
Company Quality Score
44/100
(HOLD)
Options IV Signal
18th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
Protect Your Profits
Holding RIGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 18th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.0% below Wall St target ($51.60)
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$36.49 -
$43.21
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.30
(9.5%)
Support & Resistance Levels
Support Level
$33.94
Resistance Level
$38.69
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
9.38
Wall Street Target
$51.60
(+48.0%)
Revenue Growth (YoY)
25.6%
Earnings Growth (YoY)
108.6%
Profit Margin
40.2%
Valuation Discount vs History
-2.5% cheaper
PE vs Historical
9.4 vs 10.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.5%
(market-implied from PE analysis)
1-Year Target
$33.99
(-3%)
2-Year Target
$33.14
(-5%)
3-Year Target
$32.31
(-7%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$34.80
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -44.4%)
$60.44
(+73%)
Base:
(SPY PE: 9.4, Growth: -44.4%)
$25.41
(-27%)
Bear:
(PE: 8.0, Growth: -44.4%)
$21.60
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 5.69 | Current EPS (TTM): $6.19
Bull Case
$23.29
(-33%)
Analyst growth -39.9%, PE expands to 6.3
Base Case
$21.17
(-39%)
Market implied -39.9%, PE stable at 5.7
Bear Case
$23.97
(-31%)
Severe decline -20.0%, PE contracts to 4.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.4 to 10.1
Stabilization Target:
$37.55
(+7.7%)
PE Expansion Potential:
+7.7%
Last updated: February 01, 2026 6:05 AM ET
Data refreshes hourly during market hours. Next update: 7:05 AM
Data refreshes hourly during market hours. Next update: 7:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RIGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced RIGL Option Strategies
Professional options setups generated by AI based on today's RIGL price and gamma walls.
